Skip to content
Loading…
A personalized vaccine developed by Moderna and Merck reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology. Madison Muller explains (Source:…
To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.